<DOC>
	<DOCNO>NCT00004497</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety efficacy UT-15 patient severe symptomatic primary pulmonary hypertension .</brief_summary>
	<brief_title>Phase III Randomized Study UT-15 Patients With Primary Pulmonary Hypertension</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord center etiology disease . Patients receive conventional oral therapy plus continuous subcutaneous infusion either UT-15 placebo 12 week . After complete 12 week treatment , patient may continue therapy open label UT-15 . Patients receive placebo cross receive UT-15 . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis moderate severe precapillary pulmonary hypertension ( New York Heart Association class III/IV ) unresponsive attempt use chronic oral vasodilator least 1 month Cardiac catheterization baseline : Pulmonary artery pressure least 25 mm Hg AND Pulmonary capillary wedge pressure leave ventricular end diastolic pressure great 15 mm Hg AND Pulmonary vascular resistance great 3 mm Hg/L/min Echocardiogram baseline : Right ventricular hypertrophy dilation AND Normal leave ventricular function AND Absence mitral valve stenosis Chest radiograph within prior 3 month Clear lung field OR Multiple patchy interstitial ( diffuse ) lung field AND At least 1 follow : Right ventricular enlargement Prominence main pulmonary artery Enlarged hilar vessel Decreased peripheral vessel No significant parenchymal lung disease within prior 3 month evidence : Total lung capacity great 70 % predict FEV/FVC ratio great 50 % Diffuse interstitial fibrosis alveolitis high resolution CT total lung capacity 7080 % DLCO le 60 % No chronic thromboembolic disease clot proximal lobar bifurcation Baseline exercise capacity least 50 meter walk six minute Prior/Concurrent Therapy Endocrine therapy : At least 30 day since prior chronic prostaglandin prostaglandin analogue therapy ( include Flolan IV ) No concurrent prostaglandins prostaglandin analogue Other : At least 1 month since prior new type chronic therapy ( e.g. , different category vasodilator , diuretic , digoxin ) pulmonary hypertension , except anticoagulant At least 1 week since discontinuation prior pulmonary hypertension medication , except anticoagulant At least 30 day since prior participation investigational drug study No concurrent investigational drug No concurrent chronic intravenous inhaled medication ( except oxygen ) Patient Characteristics Cardiovascular : No portal hypertension No left side heart disease define : Pulmonary capillary wedge pressure leave ventricular end diastolic pressure great 15 mm Hg OR LVEF le 40 % MUGA angiography OR LV shorten fraction le 22 % echocardiography OR Symptomatic coronary disease ( demonstrable ischemia ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Mentally physically capable use infusion pump HIV negative No disease associate pulmonary hypertension ( sickle cell anemia , schistosomiasis ) No musculoskeletal disorder ( arthritis , artificial leg , etc . ) disease limit ambulation , connect nonportable machine No concurrent physiological condition contraindicate use UT15</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 1999</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>hypertensive disorder</keyword>
	<keyword>primary pulmonary hypertension</keyword>
	<keyword>rare disease</keyword>
</DOC>